Elagolix

• Perform a pregnancy test before starting on elagolix tablets and initiate the treatment only if the test is negative to avoid the risk of early pregnancy loss. • Women taking elagolix may experience a change in the pattern of intensity and duration of menstrual bleeding which may minimize the ability to recognize the occurrence of pregnancy early. • Patients should be advised to be very careful while moving around to avoid the risk of fracture as elagolix can reduc​‍​​​​​‍​‍‍‍‍​‍‍e the bone mineral density leading to fragile or weak bones. • Taking supplements containing calcium and vitamin D during elagolix treatment may be very helpful in strengthening the bones. • New or worsening of an existing condition of depression and anxiety may occur in patients taking elagolix tablets and the patient must get immediate medical attention if suicidal ideation or behavioral changes occur. • Liver function should be evaluated regularly during the treatment with elagolix and patients should be advised to consult a doctor immediately if any symptoms or signs of liver damage such as jaundice occur. • Females of reproductive potential should be advised to use non-hormonal contraceptives during elagolix treatment as hormonal contraceptives containing estrogen can affect elagolix efficacy. • Continue with non-hormonal contraception for at least one week after taking the last dose of elagolix to avoid unexpected pregnancy.